PhII One Label Non-Comparative Trial in Metastatic Hormone Refractory Prostate Cancer in Combination With Prednisolone

Inclusion Criteria: * Men with prostate adenocarcinoma with at least one metastatic lesion which is measurable and who progressed after prior hormonal therapy. Exclusion Criteria: * 1.Body temperature \> 38 degree centigrade. * 2.Prior radiotherapy to \> 25% of bone marrow. * 3.Prior isotope therapy and/or brachytherapy * 4.Prior gene therapy. * 5.Active double cancer. * 6.Known brain or leptomeningeal involvement. * 7.History of hypersensitivity reaction to drug * 8.Other serious illness or medical condition * 9.Subjects whom the investigators consider inappropriate from social or medical aspects.